Restoring TB-specific Immunity in Early HIV Infection-the Dual Promise of Early Antiretroviral and TB Preventive Treatment. [PDF]
Moonan PK +3 more
europepmc +1 more source
Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT). [PDF]
Campbell S +9 more
europepmc +1 more source
Protocol for an in vivo CRISPR screen for germinal center B cells in mice using ecotropic retrovirus. [PDF]
Hong JP, Nussenzweig MC.
europepmc +1 more source
Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy. [PDF]
Riet T +7 more
europepmc +1 more source
First PCR-Confirmed Case of Feline Hemoplasmosis in Bosnia and Herzegovina with a Long-Term Follow-Up. [PDF]
Preldžić D +3 more
europepmc +1 more source
The HIV-1 spacer peptide P1: A novel anti-retroviral target
Human immunodeficiency virus type 1 (HIV-1) is the virus that causes AIDS. The treatment that is in current use, called highly active anti-retroviral therapy (HAART), has significantly delayed the onset of AIDS in HIV-1 infected patients.
core
Development of a Conditional Replication System Using a Lassa Virus Glycoprotein Complex-Encoding Retroviral Vector for Isolating Resistant Variants to Inhibitors in BSL-2. [PDF]
Hans MB +10 more
europepmc +1 more source
Chronic kidney disease screening and associated factors among people living with HIV on anti-retroviral therapy in Dar Es Salaam, Tanzania: Hospital-based cross-sectional study. [PDF]
Theophil M, Lyimo AA, Ambikile JS.
europepmc +1 more source
Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors. [PDF]
Okada M +4 more
europepmc +1 more source
Underweight is associated with detectable viral load among adolescents with HIV in rural eastern Uganda: a retrospective cohort study. [PDF]
Auca A, Shalah Logose B, Izudi J.
europepmc +1 more source

